Futura Medical

FM71 achieves all primary and secondary endpoints

Lighthouse | 31 August 2022

Share this note

  • Futura Medical has announced that FM71, the clinical study specifically conducted over 24 weeks to support the US FDA application for MED3000 as an OTC treatment for erectile dysfunction (ED), has met its primary and secondary endpoints. The results of FM71 were consistent with those seen in the previous 12 week FM57 Phase III study. Importantly, the improvements in erectile function were sustained throughout the longer period. The 24 week data had been explicitly requested by the FDA.
  • There were two co-primary endpoints. The first showed a highly statistically significant improvement in erectile function (p<0.001) against baseline at 24 weeks (measured by the gold standard, internationally recognised IIEF-EF score) across ‘pooled’ severities of ED (mild, moderate and severe). The second showed a 5.73 unit change in IIEF-EF score versus baseline at 24 weeks. This comfortably exceeded the 4 unit difference agreed with the FDA and defined as the Minimal Clinical Important Difference (MCID).
  • Whilst the primary endpoints focused on efficacy, the secondary endpoints examined the onset of action. The data, using FDA agreed criteria where patients experienced an erection, showed a highly statistically significant improvement (p<0.001) at 10 minutes. This endpoint was included to demonstrate a rapid onset, which the oral tadalafil 5mg tablet comparator failed to show. Typically, oral PDE5 treatments take 30-60 minutes to work.
  • Additional results from FM71 include: MED3000 exceeded the 4.0 MCID IIEF-EF score at all timepoints throughout the study; over the 24 weeks the MCID was also exceeded for each of the mild, moderate and severe ED sub-groups; and, using the SEAR (Self Esteem and Relationship) questionnaire, at week 24 85.4% of MED3000 users felt sex could be spontaneous. No serious adverse events were recorded in any patients on MED3000; 19.1% of subjects on tadalafil experienced headache versus 4.3% on MED3000; there were no instances of back pain or ‘non-cardiac’ chest pain on MED3000 versus 4.3% for each on tadalafil, whereas 4.3% on MED3000 noted nausea.

Trinity Delta view: The successful outcomes from the critical FM71 study pave the way for MED3000 to be submitted for FDA review, as a De Novo medical device, for the OTC treatment of erectile dysfunction. The dossier, including data from FM57, is expected to be submitted by end-September, with US marketing authorisation likely by end-Q123. The excellent safety and tolerability profile, coupled with the rapid onset of action and now demonstrated longer-term efficacy, means MED3000 is well positioned to become a clearly differentiated ED product. These clinical results now shift the focus from regulatory aspects to execution, much as the European CE Mark did in April 21. We expect discussions to address the commercially important US market will now begin in earnest. We currently value Futura Medical at £264m, equivalent to 92p per share but expect to review this as visibility on expected launch timings and likely commercial potential in the various markets increases.


31 August 2022

Market Cap£106.3m
Primary exchangeAIM
Company CodeFUM
Corporate clientYes

Company description

Futura Medical is an R&D driven small pharma company, with a novel DermaSys transdermal delivery platform. The lead programme, a topically applied gel (MED3000), has been approved as an OTC product for ED (erectile dysfunction) in Europe, with final trials now complete in the US.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2022 Trinity Delta Research Limited. All rights reserved.